European Journal of Pharmacology · 1995 · 10 citations · 12 references
MedicineBiochemistryPharmacologyBiochemical PharmacologyDiabetologyMetabolic RegulationCarbohydrate MetabolismDiabetes MellitusDiabetes Mellitus BiochemistryGlycemic ControlInsulin ResistanceMetabolic SyndromeAldo-keto ReductasesAldose Reductase TargetsAntidiabetic Drug TherapyGluconeogenesis Inhibition
The effect of a single oral administration of M16209 (1-(3-bromobenzo[b]furan-2-yl-sulfonyl)hydantoin), a novel aldose reductase inhibitor, on serum glucose was investigated. In normal rats, M16209 (100 mg/kg) had a weak hypoglycemic effect but markedly stimulated the disappearance of serum glucose in intravenous glucose tolerance tests. In diabetic rats, M16209 (100 mg/kg) significantly suppressed the hyperglycemia of streptozotocin-induced, mildly diabetic rats and stimulated serum glucose disappearance in neonatally streptozotocin-induced, non-insulin-dependent diabetes mellitus (NIDDM) rats in glucose tolerance tests. Additionally, M16209 augmented insulin secretion in glucose-loaded, normal and NIDDM rats and restored the reduced serum insulin in streptozotocin-induced, mildly diabetic rats. M16209, however, showed no hypoglycemic effect in severely diabetic rats. In contrast, gliclazide, a sulfonylurea, showed a much more potent hypoglycemic effect in normal rats than in mildly diabetic rats. These results suggest that M16209 suppresses hypoglycemia through augmentation of glucose-stimulated insulin secretion. The antihyperglycemic activity of M16209, combined with its potent aldose reductase inhibiting activity, is expected to be beneficial in the treatment of diabetic complications.
12
Islet Secretion in a New Experimental Model for Non-insulin-dependent Diabetes
Gordon C. Weir, E.T. Clore, Catherine J. Zmachinski et al. · Diabetes · 1981 · 239 citations